Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. (Q40401577)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

title

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Vicente Estrada

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Anna Bonjoch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Bonaventura Clotet Sala

12

object named as

Bonaventura Clotet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

6

Jordi Puig

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

9

Patricia Echeverría

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

10

Carla Estany

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

8

Arelly Ornelas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

author name string

Pere Domingo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Maria Del Mar Gutiérrez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Gracia M Mateo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Jessica Toro

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

language of work or name

English

0 references

publication date

1 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

30 March 2020

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

page(s)

844-849

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study

30 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

Body composition changes after switching from protease inhibitors to raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKW504

21 January 2018

Identifiers

DOI

10.1093/JAC/DKW504

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27999056%20AND%20SRC:MED&resulttype=core&format=json

release_glohp4xdljfbzdd6ovggxnhmha

30 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/glohp4xdljfbzdd6ovggxnhmha

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference